CAJ | 학술논문

目的：观察重组人粒细胞集落刺激因子治疗乳腺癌术后化疗后骨髓抑制的临床疗效。方法将63例乳腺癌术后化疗后骨髓抑制患者按入院的先后顺序分为2组：治疗组（32例）和对照组（31例）。2组化疗前24 h均给予地塞米松片7.5 mg口服，2次·d-1，连续3 d。化疗前30 min给予盐酸昂丹司琼8 mg加入0.9%氯化钠注射液100 mL中静脉滴注。在此基础上，治疗组化疗48 h后开始给予重组人粒细胞集落刺激因子治疗。观察2组白细胞减少、中性粒细胞数减少、血小板减少、血红蛋白减少及中性粒细胞减少性发热发生率的情况。结果治疗组血小板减少、血红蛋白减少发生率与对照组比较差异均无统计学意义（0.0%、43.8%比0.0%、45.2%，均P＞0.05）；治疗组白细胞减少、中性粒细胞数减少和中性粒细胞减少性发热发生率均较对照组明显降低（68.8%、59.4%、65.6%比96.8%、93.5%、83.9%，均P＜0.05）。结论重组人粒细胞集落刺激因子治疗乳腺癌术后化疗后骨髓抑制，能有效控制肿瘤术后化疗后骨髓抑制的发生，减少感染机会，能保障化疗的顺利进行。
목적：관찰중조인립세포집락자격인자치료유선암술후화료후골수억제적림상료효。방법장63례유선암술후화료후골수억제환자안입원적선후순서분위2조：치료조（32례）화대조조（31례）。2조화료전24 h균급여지새미송편7.5 mg구복，2차·d-1，련속3 d。화료전30 min급여염산앙단사경8 mg가입0.9%록화납주사액100 mL중정맥적주。재차기출상，치료조화료48 h후개시급여중조인립세포집락자격인자치료。관찰2조백세포감소、중성립세포수감소、혈소판감소、혈홍단백감소급중성립세포감소성발열발생솔적정황。결과치료조혈소판감소、혈홍단백감소발생솔여대조조비교차이균무통계학의의（0.0%、43.8%비0.0%、45.2%，균P＞0.05）；치료조백세포감소、중성립세포수감소화중성립세포감소성발열발생솔균교대조조명현강저（68.8%、59.4%、65.6%비96.8%、93.5%、83.9%，균P＜0.05）。결론중조인립세포집락자격인자치료유선암술후화료후골수억제，능유효공제종류술후화료후골수억제적발생，감소감염궤회，능보장화료적순리진행。
Objective To observe the curative effect of recombinant human granulocyte colony-stimulating factor on chemotherapy-induced myelosuppression after breast cancer surgery. Methods According to the order of admission,63 patients with chemotherapy-induced myelosuppression after breast cancer surgery were divided into two groups: treatment group (n=32) and control group (n=31). At 24 hours before chemotherapy, all patients were given oral dexamethasone tablets 7.5 mg twice daily for 3 days. At 30 minutes before chemotherapy,patients were intravenously injected with ondansetron hydrochloride 8 mg in 0.9% sodium chloride injection 100 mL. In addition,patients in treatment group were given recombinant human granulocyte colony-stimulating factor after chemotherapy for 48 hours. The incidences of leukopenia,neutropenia,thrombocytopenia,hemoglobin reduction and neutropenic fever were observed in both groups. Results There were no significant differences in incidences of thromboc-ytopenia and hemoglobin reduction between treatment group and control group(0.0%vs 0.0%and 43.8%vs 45.2%, respectively;P>0.05). Compared with control group, the incidences of leukopenia, neutropenia and neutropenic fever significantly decreased in treatment group (68.8%vs 96.8%, 59.4% vs 93.5% and 65.6%vs 83.9%,respectively;P<0.05). Conclusion Recombinant human granulocyte colony-stimulating factor can effectively control the occurrence of chemotherapy-induced myelosuppression after breast cancer surgery, reduce the chances of infection, and ensure the smooth progress of chemotherapy.